1. Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. NAT REV DRUG DISCOV 2019;18: 197–218.
2. Todryk S, Jozwik A, de Havilland J, Hester J. Emerging Cellular Therapies: T Cells and Beyond. CELLS-BASEL 2019;8.
3. Jiang N, Qiao G, Wang X, et al.. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. CLIN CANCER RES 2017;23: 5066-73.
4. Qiao G, Wang X, Zhou X, et al.. Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors. Int J Hyperthermia 2019;36: 74–82.
5. Wang S, Wang X, Zhou X, Lyerly HK, Morse MA, Ren J. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin Biol Ther 2020;20: 601-7.
6. Elkrief A, Derosa L, Zitvogel L, Kroemer G, Routy B. The intimate relationship between gut microbiota and cancer immunotherapy. Gut Microbes 2019;10: 424-8.
7. Abu-Sbeih H, Wang Y. Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis. Dig Dis Sci 2020;65: 797-9.
8. Wang Y, Wiesnoski DH, Helmink BA, et al.. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. NAT MED 2018;24: 1804-8.
9. Lee KA, Shaw HM, Bataille V, Nathan P, Spector TD. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications. EUR J CANCER 2020;138: 149 − 55.
10. Gopalakrishnan V, Spencer CN, Nezi L, et al.. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. SCIENCE 2018;359: 97–103.
11. Uribe-Herranz M, Bittinger K, Rafail S, et al.. Gut microbiota modulates adoptive cell therapy via CD8alpha dendritic cells and IL-12. JCI Insight 2018;3.
12. Paulos CM, Wrzesinski C, Kaiser A, et al.. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8 + T cells via TLR4 signaling. J CLIN INVEST 2007;117: 2197 − 204.
13. Castillo DJ, Rifkin RF, Cowan DA, Potgieter M. The Healthy Human Blood Microbiome: Fact or Fiction? Front Cell Infect Microbiol 2019;9: 148.
14. Ouaknine KJ, Helly DTP, Dumenil C, et al.. Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. J IMMUNOTHER CANCER 2019;7: 176.
15. Yang S, Lin S, Kelen GD, et al.. Quantitative multiprobe PCR assay for simultaneous detection and identification to species level of bacterial pathogens. J CLIN MICROBIOL 2002;40: 3449-54.
16. Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. BIOINFORMATICS 2011;27: 2957-63.
17. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. NAT METHODS 2013;10: 996-8.
18. Edgar RC, Haas BJ, Clemente JC, Quince C, Knight R. UCHIME improves sensitivity and speed of chimera detection. BIOINFORMATICS 2011;27: 2194 − 200.
19. Caporaso JG, Kuczynski J, Stombaugh J, et al.. QIIME allows analysis of high-throughput community sequencing data. NAT METHODS 2010;7: 335-6.
20. Edgar RC. Search and clustering orders of magnitude faster than BLAST. BIOINFORMATICS 2010;26: 2460-1.
21. Schloss PD, Westcott SL, Ryabin T, et al.. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009;75: 7537-41.
22. Emens LA, Ascierto PA, Darcy PK, et al.. Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. EUR J CANCER 2017;81: 116 − 29.
23. Kruger S, Ilmer M, Kobold S, et al.. Advances in cancer immunotherapy 2019 - latest trends. J Exp Clin Cancer Res 2019;38: 268.
24. Introna M. CIK as therapeutic agents against tumors. J AUTOIMMUN 2017;85: 32–44.
25. Garofano F, Gonzalez-Carmona MA, Skowasch D, et al.. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. INT J MOL SCI 2019;20.
26. Shirjang S, Alizadeh N, Mansoori B, et al.. Promising immunotherapy: Highlighting cytokine-induced killer cells. J CELL BIOCHEM 2019;120: 8863-83.
27. Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy. CANCER CELL 2018;33: 570 − 80.
28. Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R. How the Intricate Interaction among Toll-Like Receptors, Microbiota, and Intestinal Immunity Can Influence Gastrointestinal Pathology. J IMMUNOL RES 2015;2015: 489821.
29. McQuade JL, Daniel CR, Helmink BA, Wargo JA. Modulating the microbiome to improve therapeutic response in cancer. LANCET ONCOL 2019;20: e77-91.
30. Hodgins JJ, Khan ST, Park MM, Auer RC, Ardolino M. Killers 2.0: NK cell therapies at the forefront of cancer control. J CLIN INVEST 2019;129: 3499 − 510.
31. Morvan MG, Lanier LL. NK cells and cancer: you can teach innate cells new tricks. NAT REV CANCER 2016;16: 7–19.
32. Liu C, Hu Q, Hu K, et al.. Increased CD8 + CD28 + T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer. J TRANSL MED 2019;17: 120.
33. Huang L, Qiao G, Morse MA, et al.. Predictive significance of T cell subset changes during ex vivo generation of adoptive cellular therapy products for the treatment of advanced non-small cell lung cancer. ONCOL LETT 2019;18: 5717-24.
34. Gibiino G, Lopetuso LR, Scaldaferri F, Rizzatti G, Binda C, Gasbarrini A. Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals. Dig Liver Dis 2018;50: 635-9.
35. Wardill HR, Bowen JM. Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care 2013;7: 155 − 61.
36. Wirtz S, Neufert C, Weigmann B, Neurath MF. Chemically induced mouse models of intestinal inflammation. NAT PROTOC 2007;2: 541-6.
37. Spadoni I, Zagato E, Bertocchi A, et al.. A gut-vascular barrier controls the systemic dissemination of bacteria. SCIENCE 2015;350: 830-4.
38. Poggi A, Benelli R, Vene R, et al.. Human Gut-Associated Natural Killer Cells in Health and Disease. FRONT IMMUNOL 2019;10: 961.
39. Routy B, Le Chatelier E, Derosa L, et al.. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. SCIENCE 2018;359: 91 − 7.
40. Matson V, Fessler J, Bao R, et al.. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. SCIENCE 2018;359: 104-8.
41. Vivarelli S, Salemi R, Candido S, et al.. Gut Microbiota and Cancer: From Pathogenesis to Therapy. Cancers (Basel) 2019;11.
42. Vetizou M, Pitt JM, Daillere R, et al.. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. SCIENCE 2015;350: 1079-84.
43. Brandi G, Frega G. Microbiota: Overview and Implication in Immunotherapy-Based Cancer Treatments. INT J MOL SCI 2019;20.
44. Schwartz DJ, Rebeck ON, Dantas G. Complex interactions between the microbiome and cancer immune therapy. Crit Rev Clin Lab Sci 2019;56: 567 − 85.
45. Potgieter M, Bester J, Kell DB, Pretorius E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS MICROBIOL REV 2015;39: 567 − 91.